fda drug shortage list semaglutide The GLP-1 is over. What's next for the compounders? - Pharma Technology Focus The Risks of Compounded Semaglutide

This promotes the accumulation of fat in the abdomen and liver, as well as creating insulin resistance

Trends Endocrinol Metab (2020) 31(4):27686

Retatrutides clinical performance is certainly noteworthy, but the next challenge extends beyond efficacy and into evidence translation, regulatory acceptance, and commercial scalability

demonstrated, in addition to higher weight loss in the group treated with high-dose liraglutide 3.0 mg/day for 32 weeks, significant improvements not only of fasting glucose and HOMA-IR, but also of the post-load glucose measured by OGTT, OGTT-derived insulin sensitivity index (SIOGTT), and corrected the early insulin response to a glucose challenge (IGI/HOMA) compared to placebo [62]